BioSpace News Archive

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced it has expanded the scope of its existing research program with the Julius-Maximilians-University Wuerzburg, on the development of COVID-19 and Chlamydia trachomatis vaccines.

Autolus Therapeutics plc announced its operational and financial results for the fourth quarter and full year ended December 31, 2021.

Bioventus Inc., a global leader in innovations for active healing, reported financial results for the fourth quarter and full-year ended December 31, 2021.

BioXcel Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic initiatives.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings on March 15, 2022, at the 32nd Annual Oppenheimer Healthcare Conference.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), today announced that it has signed an agreement with Cervos Inc. (“Cervos Medical”) to become the exclusive distributor of Marrow Cellution™ devices for use in urology, gynecology, and male and female sexual dysfunction.

LiVeritas Biosciences, Inc. announced that it is now offering transformative mass spectrometry outsourcing solutions to biopharma enterprises from a new state-of-the-art laboratory in South San Francisco, empowering clients to achieve accelerated drug development milestones.

Pattern Bioscience, Inc. announced the appointment of Carey-Ann Burnham, PhD, as chief clinical officer.

Zealand Pharma:Significant Advancement of Clinical Pipeline and Building Commercial Momentum.